CME/CPE/MOC Credit Tracker

Transcription

1 CME/CPE/MOC Credit Tracker Use the CME/CPE/MOC Tracker below as a guide to track the sessions you ve attended, then go to to enter your sessions, complete a short evaluation for each session, and claim CME/CPE/MOC credit. In accordance with ACCME guidelines, and to ensure balanced presentations, at least one IDWeek Program Committee member will serve as a moderator of each session. IDSA, in conjunction with ProCE, Inc. will offer pharmacists continuing pharmacy education (CPE) credit for select sessions. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. PW01 The Vincent T. Andriole ID Board Review Course ($) Maximum of 7.5 AMA PRA PW02 Best Practices for Antimicrobial Stewardship Programs ($) Maximum of 7.5 AMA PRA PW03 NIH Initiatives/Grant Writing Workshop Maximum of AMA PRA PW06 TB Workshop ($) Maximum of AMA PRA PW07 Hepatitis C Workshop Maximum of AMA PRA PW08 A Sociobehavioral Approach to Infection Prevention and Antimicrobial Stewardship Maximum of AMA PRA PW09 How to Use EBM/GRADE to Develop Guidelines Maximum of AMA PRA PW10 Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Module: General ID 2018 Maximum of 15 AMA PRA PW11 Medication Assisted Treatment Waiver Course Maximum of AMA PRA 1 Challenging Cases in Pediatric Infectious Diseases Maximum of 1.75 AMA PRA 2 Late Breaker Ebola Update Maximum of 1.75 AMA PRA 3 Machine Learning and Modeling in Infectious Diseases Maximum of 1.75 AMA PRA RCT That Will Change Your Practice Maximum of 1.75 AMA PRA 5 Stewardship: Best Drivers of Change Debate Maximum of 1.75 AMA PRA 6 Update on Biofilm-Related Infections Maximum of 1.75 AMA PRA 7 What s Hot in ID + HIV Maximum of 1.75 AMA PRA 8 Opening Plenary Maximum of 1.5 AMA PRA 11 Are You Ready? Outbreak Response Training Maximum of 1 AMA PRA 12 Disease Eradication Progress: Polio and Guinea Worm Maximum of 1 AMA PRA 13 Emerging Issues in the Diagnosis of STIs Maximum of 1 AMA PRA 1 How to Build Allergy Testing into Your Stewardship Program Maximum of 1 AMA PRA 15 NTM Infections: Challenges in Diagnosis and Management Maximum of 1 AMA PRA 16 Our Most Difficult HIV Cases (other than STIs) Maximum of 1 AMA PRA 17 Questions in Bacteremia Maximum of 1 AMA PRA 18 Respiratory Infections in Pregnant Women Maximum of 1 AMA PRA 19 Shall We Agree to Disagree: Management of Pediatric Acute Hematogenous Osteomyelitis Maximum of 1 AMA PRA 20 Women in ID Maximum of 1 AMA PRA 21 Brain on Fire : Challenging Cases in Infectious and Inflammatory Encephalitis Maximum of 1.25 AMA PRA 22 Case-Based Problems in Vaccines: Beyond the Guidelines Maximum of 1.25 AMA PRA L01-P L01-P L01-P L01-P L01-P L01-P L01-P L01-P L0-P L01-P L02-P L01-P L0-P L01-P L01-P L01-P L01-P L01-P L0-P L01-P L0-P 52 Final Program IDWeek 2018

2 23 Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium Maximum of 1.25 AMA PRA 2 Can You Hear and See Me Now? ID Telehealth Maximum of 1.25 AMA PRA 25 Combating Antimicrobial Resistance: Relevance of the One Health Concept Maximum of 1.25 AMA PRA 26 Just Your Average Day in a Pediatric Infectious Disease Clinic Maximum of 1.25 AMA PRA 27 Predict, Prevent, and Protect: Optimizing Transplant Outcomes Maximum of 1.25 AMA PRA 28 Still at Highest Risk: Innovative Approaches & Urgent Needs for Prevention and Care Maximum of 1.25 AMA PRA 29 What Are You Talking About? Communication Strategies for Stewardship Programs Maximum of 1.25 AMA PRA 3 Diagnostic Clinical Cases Maximum of 1.25 AMA PRA 35 STIs in the HIV Care Setting Maximum of 1.25 AMA PRA 36 Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship Maximum of 1.25 AMA PRA 37 Hepatitis B: Current and Future Challenges in Treatment and Prevention Maximum of 1.25 AMA PRA 38 Hot Topics in Medical Education 2018 Maximum of 1.25 AMA PRA 39 Hot Topics in Pediatric Infectious Diseases Maximum of 1.25 AMA PRA 0 Improving Healthcare-Associated Infection Metrics Maximum of 1.25 AMA PRA 1 New and Updated Guidelines Maximum of 1.25 AMA PRA 2 The Microbiome and Multidrug-Resistant Organisms Maximum of 1.25 AMA PRA 3 Tuberculosis: What s New in Diagnosis and Management Maximum of 1.25 AMA PRA 75 Clinical Controversies Maximum of 1.25 AMA PRA 76 Controversies in Infection Prevention Maximum of 1.25 AMA PRA 77 Mano-a-Mano III : Controversies in Pediatric ID Maximum of 1.25 AMA PRA 78 Bread and Butter Transplant ID Maximum of 1.25 AMA PRA 80 Migration and Immigration: Global Diseases at Your Doorstep Maximum of 1.25 AMA PRA 81 New Developments on Picornaviruses Maximum of 1.5 AMA PRA 82 Novel Clinical Risks for Fungal Disease Maximum of 1.25 AMA PRA 83 The Human Microbiome in HIV Maximum of 1.25 AMA PRA 88 John F. Enders Lecture Maximum of 0.25 AMA PRA 91 Maxwell Finland Lecture Maximum of 0.25 AMA PRA 93 Ask the Expert: Managing Invasive Fungal Infections Maximum of 1 AMA PRA 9 Challenging STIs in the HIV Infected Patient Maximum of 1 AMA PRA 95 Controversies in Sepsis (but not SIRS) Maximum of 1 AMA PRA 96 Designing a QI Project You Can Publish Maximum of 1 AMA PRA 97 Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era Maximum of 1 AMA PRA 98 ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs Maximum of 1 AMA PRA L01-P L0-P L01-P L01-P L01-P L0-P L0-P L02-P L0-P L01-P L0-P L0-P L01-P L01-P L01-P L01-P L0-P L01-P L0-P L01-P L02-P L0-P L0-P L01-P L02-P L0-P L0-P L01-P continued on next page Final Program IDWeek

3 99 Microbiome Therapeutics Maximum of 1 AMA PRA 100 Mid-Career Challenges and Opportunities Maximum of 1 AMA PRA 101 Tropical Dermatology: Are You Ready for Jeopardy? Maximum of 1 AMA PRA 102 Using Mathematical Modeling to Inform HAI Prevention: Fresh Perspectives on Old Problems Maximum of 1 AMA PRA 103 Achy Breaky Heart : Challenging Cases in Cardiovascular Infections Maximum of 1.25 AMA PRA 10 A Day with the Hospital Epidemiologist s Beeper: Challenging Cases in Infection Prevention Maximum of 1.25 AMA PRA 105 Advances in RSV Prevention Maximum of 1.25 AMA PRA 106 Fungal MDR Outbreak: Candida auris Maximum of 1.25 AMA PRA 107 HIV State of the Art Maximum of 1.25 AMA PRA 108 Metagenomic-Based Infectious Disease Diagnostics Maximum of 1.25 AMA PRA 109 Pandemic Influenza Maximum of 1.25 AMA PRA 110 Secret Sauce for Effective Vaccines: Adjuvants and Effective Immune Responses Maximum of 1.25 AMA PRA 111 Stewardship in Challenging Populations Maximum of 1.25 AMA PRA 116 Challenging Cases in Infectious Diseases Maximum of 1.25 AMA PRA 117 Big Beasts I Maximum of 1.25 AMA PRA 118 How to Treat Resistant Gram-Positive Infections Maximum of 1.25 AMA PRA 119 Infection Control and Antimicrobial Stewardship in Dialysis Facilities Maximum of 1.25 AMA PRA 120 Late Breaker Foodborne Illnesses Maximum of 1.25 AMA PRA 121 Pathogen Interactions with the Microbiota Maximum of 1.25 AMA PRA 122 Strategies to Achieve HIV Remission Maximum of 1.25 AMA PRA 123 Time 101: Optimizing Meetings Maximum of 1.25 AMA PRA 129 Caroline B. Hall Lectureship Maximum of 1.25 AMA PRA 156 Challenging Cases in Transplant: When the ID Expert Says, What? Maximum of 1.25 AMA PRA 157 Challenging HIV Cases Maximum of 1.25 AMA PRA 158 Beyond the Big Beasts of Healthcare Epidemiology Maximum of 1.25 AMA PRA 159 Laboratory Diagnosis of Bloodstream Infections: New Technologies and Continuing Challenges Maximum of 1.25 AMA PRA 160 Leading Change Maximum of 1.25 AMA PRA 161 Pediatric Immunization: Perspectives From Both Sides of the Pond Maximum of 1.25 AMA PRA 162 T-Cell Biology: What the ID Physician Needs to Know Maximum of 1.25 AMA PRA 163 The ID Specialist and the Opioid Epidemic: What You Need to Know Now Maximum of 1.25 AMA PRA 16 Vaccines Against Herpesviruses Maximum of 1.25 AMA PRA 170 Diagnostic Updates: Clinical Mycology Update Maximum of 1.25 AMA PRA 171 ID Physicians in the Age of Value-Based Healthcare Maximum of 1.25 AMA PRA 172 My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections Maximum of 1.25 AMA PRA L01-P L0-P L01-P L0-P L01-P L01-P L01-P L02-P L0-P L01-P L0-P L0-P L01-P L01-P L01-P L0-P L01-P L02-P L0-P L01-P L01-P L02-P L01-P L01-P L0-P L01-P L0-P L01-P L01-P L01-P L0-P L01-P 5 Final Program IDWeek 2018

4 173 SHEA Lecture: A Wrinkle in Time: Reflections on Advances and Unmet Needs in Healthcare Epidemiology Maximum of 1.25 AMA PRA 176 Influential Publications in Antimicrobial Stewardship from the Past Year Maximum of 1.25 AMA PRA 177 Stanley A. Plotkin Lectureship in Vaccinology Maximum of 1.25 AMA PRA 179 B-lactam / B-lactamase Inhibitor Combinations: Which one? Maximum of 1 AMA PRA 180 Clinical Teaching for the ID Provider Maximum of 1 AMA PRA 181 Creepy, Dreadful, Wonderful Parasites and Other Creatures Maximum of 1 AMA PRA 182 Diagnosing & Preventing Urinary Tract Infection: Science, Behavior Change, & Aha Moments Maximum of 1 AMA PRA 183 Diagnosis of Toxoplasmosis in Special Populations Maximum of 1 AMA PRA 18 Dollar Dollar Bills Y All: Billing and Coding in ID Maximum of 1 AMA PRA 185 Educating Trainees about Stewardship Maximum of 1 AMA PRA 186 Emerging Drug Resistance in STIs Maximum of 1 AMA PRA 187 NHSN Update Maximum of 1 AMA PRA 188 Rapid Fire: Curbsides in Transplant ID Maximum of 1 AMA PRA 189 Updates from the Antibacterial Resistance Leadership Group Maximum of 1 AMA PRA 190 Shots Across the Bow: Debates in Vaccinology Maximum of 1.25 AMA PRA 191 Big Beasts II Maximum of 1.25 AMA PRA 192 Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs Maximum of 1.25 AMA PRA 193 ID Physicians and Addiction Medicine Maximum of 1.25 AMA PRA 19 Malignancies in Patients with HIV Maximum of 1.25 AMA PRA 195 Neonatal Infectious Disease: Chagas, Zika, and LCMV Maximum of 1.25 AMA PRA 196 Non-Zika Arboviruses in the Americas Maximum of 1.25 AMA PRA 197 Pediatric Infection Prevention: Small Patients, Big Challenges Maximum of 1.25 AMA PRA 198 The Future of Transplant ID: Novel Diagnostics and Therapeutics Maximum of 1.25 AMA PRA 203 Tropical Medicine Cases: Conundrums and Case Management Maximum of 1.25 AMA PRA 20 Advances in Transplantation for Patients with HIV Maximum of 1.25 AMA PRA 205 Changing Landscape of Rapid Diagnostic Tests and Their Impact Maximum of 1.25 AMA PRA 206 Controlling Antimicrobial Resistance Across Borders Maximum of 1.25 AMA PRA 207 Cool Ways to Discover Antibiotics Maximum of 1.25 AMA PRA 208 I m Better than You and I Can Prove It: Quality Metrics for Clinical ID Maximum of 1.25 AMA PRA 209 Infections in Immunocompromised Hosts Maximum of 1.25 AMA PRA 210 Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future Maximum of 1.25 AMA PRA 260 Advances in Epidemiology Research Methods Maximum of 1.25 AMA PRA 261 Infection Prevention in Post-Acute Care: Controversies and Challenges Maximum of 1.25 AMA PRA 262 Intersection of Surgery and Pediatric Infectious Disease Maximum of 1.25 AMA PRA L0-P L0-P L01-P L01-P L01-P L0-P L01-P L01-P L01-P L01-P L01-P L01-P L02-P L01-P L01-P L01-P L01-P L01-P L02-P L0-P L0-P L0-P L0-P L01-P L0-P L01-P L01-P continued on next page Final Program IDWeek

5 263 Old Foes and Emerging Threats: Multidrug-Resistant Bacterial Infections in Children Maximum of 1.25 AMA PRA 26 Pain Management and Mental Health in Patients with HIV Maximum of 1.25 AMA PRA 265 Strategy Trials: A New Paradigm in Infectious Diseases Research Maximum of 1.25 AMA PRA 266 Syphilis in the 21st Century Maximum of 1.25 AMA PRA 267 When Does PK/PD Matter for Patient Care? Maximum of 1.25 AMA PRA 268 When Transplant Tours the World Maximum of 1.25 AMA PRA 273 Joseph E. Smadel Lecture Maximum of 0.25 AMA PRA 276 Edward H. Kass Lecture Maximum of 0.25 AMA PRA 277 ID BugBowl Maximum of 1 AMA PRA 278 Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics Maximum of 1 AMA PRA 279 Red Book Update Maximum of 1 AMA PRA 280 Tele-Antimicrobial Stewardship Maximum of 1 AMA PRA 281 Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic- Resistant Infections Maximum of 1.5 AMA PRA L01-P L02-P L0-P L01-P L0-P L01-P L0-P L02-P L0-P L0-P L01-P 56 Final Program IDWeek 2018